These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29294465)

  • 21. The Influence of GnRH Analog Therapy on Growth in Central Precocious Puberty.
    Głąb E; Wikiera B; Bieniasz J; Barg E
    Adv Clin Exp Med; 2016; 25(1):27-32. PubMed ID: 26935495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical effects of gonadotropin-releasing hormone agonists for the treatment of children patients with central precocious puberty.
    Xue Y; Wang P; Wang SQ; Gao YQ
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):5014-5017. PubMed ID: 30070338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height.
    Comite F; Cassorla F; Barnes KM; Hench KD; Dwyer A; Skerda MC; Loriaux DL; Cutler GB; Pescovitz OH
    JAMA; 1986 May; 255(19):2613-6. PubMed ID: 3084811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LHRH analog treatment of central precocious puberty complicating congenital adrenal hyperplasia.
    Pescovitz OH; Cassorla F; Comite F; Loriaux DL; Cutler GB
    Ann N Y Acad Sci; 1985; 458():174-81. PubMed ID: 3911847
    [No Abstract]   [Full Text] [Related]  

  • 27. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
    Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
    Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
    Antoniazzi F; Bertoldo F; Lauriola S; Sirpresi S; Gasperi E; Zamboni G; Tatò L
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1992-6. PubMed ID: 10372699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different effects of agonistic vs. antagonistic gnrh-analogues (triptorelin vs. cetrorelix) on bone modeling and remodeling in peripubertal female rats.
    Roth CL; Neu C; Jarry H; Schoenau E
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):451-6. PubMed ID: 16151979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of precocious puberty by GnRH agonists].
    Carel JC
    Ann Urol (Paris); 2005 Oct; 39 Suppl 3():S85-8. PubMed ID: 16302717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist.
    Yeshaya A; Kauschansky A; Orvieto R; Varsano I; Nussinovitch M; Ben-Rafael Z
    Acta Obstet Gynecol Scand; 1998 Mar; 77(3):327-9. PubMed ID: 9539281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of precocious puberty with an LH-RH agonist (D-TRP6-LH-RH delayed-release microcapsules)].
    Canlorbe P; Chaussain JL; Lahlou N; Roger M; Toublanc JE; Job JC
    Bull Acad Natl Med; 1988 Nov; 172(8):1091-8. PubMed ID: 2977732
    [No Abstract]   [Full Text] [Related]  

  • 33. Adrenarche and skeletal maturation during luteinizing hormone releasing hormone analogue suppression of gonadarche.
    Wierman ME; Beardsworth DE; Crawford JD; Crigler JF; Mansfield MJ; Bode HH; Boepple PA; Kushner DC; Crowley WF
    J Clin Invest; 1986 Jan; 77(1):121-6. PubMed ID: 2935557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Improvement in the prognosis for growth in a boy with central precocious puberty and growth hormone deficiency treated concurrently with growth hormone and D-Trp-6-LHRH gonadoliberin analog].
    Snajderová M; Lebl J; Zemková D; Kolousková S; Pechová M
    Cesk Pediatr; 1994; 49(1):25-8. PubMed ID: 8124746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The side effects of gonadotropin releasing hormone analog (diphereline) in treatment of idiopathic central precocious puberty.
    Karamizadeh Z; Tabebordbar M; Saki F; Karamifar H; Amirhakimi G
    Acta Med Iran; 2013; 51(1):41-6. PubMed ID: 23456583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
    Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The significance and characteristics of the LHRH test in diagnosing precocious puberty development in girls: the stimulated LH/FSH quotient differentiates between central precocious puberty and premature thelarche].
    Partsch CJ; Hümmelink R; Lorenzen F; Sippell WG
    Monatsschr Kinderheilkd; 1989 May; 137(5):284-8. PubMed ID: 2525665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC; Roger M; Ispas S; Tondu F; Lahlou N; Blumberg J; Chaussain JL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.